Modality
Small Molecule
MOA
FGFRi
Target
TNFα
Pathway
Complement
RCC
Development Pipeline
Preclinical
~Mar 2016
→ ~Jun 2017
Phase 1
Sep 2017
→ Jul 2025
Phase 1Current
NCT03117012
2,039 pts·RCC
2025-07→TBD·Not yet recruiting
NCT08032822
78 pts·RCC
2017-09→TBD·Not yet recruiting
2,117 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Trial Timeline
Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3
P1/2
Not yet…
P1/2
Not yet…
Not yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03117012 | Phase 1/2 | RCC | Not yet recr... | 2039 | eGFR |
| NCT08032822 | Phase 1/2 | RCC | Not yet recr... | 78 | ACR20 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-9749 | Eli Lilly | Phase 3 | C5 | |
| LLY-1956 | Eli Lilly | Phase 1/2 | BCMA | |
| ABB-3951 | AbbVie | Phase 2/3 | TNFα | |
| GIL-6239 | Gilead Sciences | Phase 2 | TNFα | |
| MRN-8225 | Moderna | Preclinical | TNFα | |
| Sovanaritide | Argenx | Phase 3 | TNFα | |
| SRP-9822 | Sarepta | Phase 3 | SOS1 | |
| 369-4107 | Hansoh Pharma | Phase 2 | TNFα | |
| Rimainavolisib | Illumina | Phase 2 | PD-1 | |
| Elrainavolisib | Roivant Sciences | Preclinical | Nectin-4 |